Price History
Feb 9, 2026 — Apr 4, 2026Investment Snapshot
- P/E of 1.3 — trading at a low earnings multiple
- Piotroski F-Score 5/9 — moderate financial health
- Loss-making — negative ROE of -49.1%
biote Corp. (BTMD) is a Healthcare company operating in Medicinal Chemicals & Botanical Products, listed on the NASDAQ , with a market capitalisation of $45 million . Key value metrics: P/E ratio 1.3, Piotroski F-Score 5 out of 9 (moderate financial health) .
Value Score
Key Metrics
Current vs 5-Year Average
Based on 4 years of SEC filingsRevenue & Net Income
Financial Statements
| Metric | FY22 | FY23 | FY24 |
|---|---|---|---|
| Revenue | $X.XB | $X.XB | $X.XB |
| Gross Profit | $X.XB | $X.XB | $X.XB |
| Operating Income | $X.XB | $X.XB | $X.XB |
| Net Income | $X.XB | $X.XB | $X.XB |
| EBITDA | $X.XB | $X.XB | $X.XB |
| Total Assets | $X.XB | $X.XB | $X.XB |
| Total Liabilities | $X.XB | $X.XB | $X.XB |
biote Corp. — Fundamental Analysis Summary
biote Corp. (BTMD) trades at a trailing P/E of 1.3x — 95% below the Healthcare sector average of 25.3x.
On financial health, BTMD shows a moderate Piotroski F-Score of 5/9, and negative return on equity of -49.1% (sector average: -19.8%).
StockPik's composite Value Score for BTMD is 85/100 — placing it in undervalued territory. The score is built from ten fundamental signals: P/E, P/B, PEG ratio, P/S ratio, return on equity, gross margin, debt-to-equity, current ratio, dividend yield, and Piotroski F-Score.
BTMD shows revenue declining at 3% year-over-year, with earnings growing at 757%.